It’s no secret that the medtech industry’s response to COVID-19 has been fierce, innovative and dynamic. The world cried out for tests to track the infection, technology to develop treatments, ventilators to help people breathe and the machinery to bring vaccines to millions. At the same time, many companies rearranged their efforts to address the new threat, while all were forced to adapt to its effects: lockdowns closed laboratories, and offices became chatrooms.
Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes that much more significant. Even more significant, their advancements all have the potential to deliver changes in care that will outlast this pandemic.
This includes using artificial intelligence to sift massive amounts of data in search of a treatment that may connect with our global ailment or employing gene editing and diagnostics-on-demand to quickly identify the disease wherever needed.
Others use technology to guide the hands of a professional, the eyes of a pathologist or the beat of the heart itself. They can help us observe the health of the brain and the inner workings of cells, or ensure the safety of a new mother.
There’s always more work to do, but each advancement in the medtech industry makes those hills easier to climb—for physicians, clinicians, treatment developers and above all, for patients— because any success attained in this field rarely remains with the company. — Conor Hale